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Abstract
Topical gene delivery to the epidermis has the potential to be an effective therapy for skin disorders, cutaneous cancers,
vaccinations and systemic metabolic diseases. Previously, we reported on a non-invasive multielectrode array (MEA) that
efficiently delivered plasmid DNA and enhanced expression to the skin of several animal models by in vivo gene
electrotransfer. Here, we characterized plasmid DNA delivery with the MEA in a hairless guinea pig model, which has a
similar histology and structure to human skin. Significant elevation of gene expression up to 4 logs was achieved with
intradermal DNA administration followed by topical non-invasive skin gene electrotransfer. This delivery produced gene
expression in the skin of hairless guinea pig up to 12 to 15 days. Gene expression was observed exclusively in the epidermis.
Skin gene electrotransfer with the MEA resulted in only minimal and mild skin changes. A low level of human Factor IX was
detected in the plasma of hairless guinea pig after gene electrotransfer with the MEA, although a significant increase of
Factor IX was obtained in the skin of animals. These results suggest gene electrotransfer with the MEA can be a safe,
efficient, non-invasive skin delivery method for skin disorders, vaccinations and potential systemic diseases where low levels
of gene products are sufficient.
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Introduction
Epidermal gene transfer is suggested as a new therapeutic
strategy for a variety of skin diseases, vaccination and systemic
disorders [1–5]. Long-term or persistent gene delivery to the
epidermis has promise for inherited skin diseases and potentially
systemic disorders [3,5]. On the other hand, short-term epidermal
gene delivery is suitable for vaccination, skin wound or ulcer
therapies and skin malignancy [2–6]. Topical application of
plasmid DNA results in low levels and short duration of gene
expression in epidermal skin [7]. Cutaneous gene electrotransfer
(GET) following intradermal DNA injection has been widely
studied [8]. The level and duration of gene expression is quite
different, depending on which type of electrodes and which species
of animals was utilized [8–14]. However, definitive epidermal
expression by GET in guinea pig or human skin xenograft mouse
model has been demonstrated by only a few groups of researchers
[9,12,15,16].
The human skin xenograft mouse model may be the best choice
for preclinical skin research [17–19]. However, sources of human
skin are very limited. A second option is hairless guinea pig
(HLGP) skin, whose skin is very similar to human skin
anatomically and histologically as opposed to the skin of normal
rodents [20]. Previously, we [12,16] demonstrated that GET to
the skin resulted in efficient expression in rat and the Hartley
guinea pig (haired). In this study, we further characterize several
important aspects associated with potential clinical applications,
such as the level and duration of gene expression, distribution of
gene expression within the tissue and side effects in this model. We
also investigated if a therapeutic protein, human factor IX, could
be expressed in the skin following delivery using the non-invasive
MEA and whether it could reach the blood circulation.
Materials and Methods
Animals
Female IAF hairless guinea pigs (Charles River, Wilmington,
MA, USA) used in this study were 160 g to 200 g in weight. All
experimental procedures were approved by the Institutional
Animal Care and Use Committee of Old Dominion University.
All treatment was performed under isoflurane anesthesia, and all
efforts were made to minimize suffering.
Plasmids
The reporter plasmids encoded luciferase (gWiz-Luc) and green
fluorescent protein (gWiz-GFP), were acquired from Aldevron
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(Fargo, ND, USA). Human Factor IX expression vector
pNGVL3/CMVi/hFIXm1given by Dr. Kurachi was commer-
cially prepared by Aldevron. All three plasmids are with a CMV
promoter.
DNA Injection and in vivo Gene Electrotransfer
Prior to delivery, animals were anesthetized in an induction
chamber charged with 3% isoflurane in O2 then fitted with a
standard rodent mask and kept under general anesthesia during
the procedure. Guinea pigs received intradermal injections of
50 ml or 200 ml plasmid DNA (2 mg/ mL dissolved in saline) on the
left and/or right flank. Immediately after DNA administration, a
MEA electrode with 464 2-mm-apart pins was placed over the
injection site(s). Each pair of electrodes was programmed to
administer four pulses with total 72 pulses [16]. The applied
voltage varied between 30–70 V between the two pins of the MEA
which was set at 2 mm to achieve nominal field strengths between
150 – 350 V/cm, each pulse duration was 150 ms with a 150 ms
delay. Electrotransfer was performed using the UltraVolt Model:
Rack-2-500-00230 (Ultravolt, Inc. Ronkonkoma, NY, USA). For
four 50 ml adjacent injections, four individual pulse applications
were applied without a change of pulse parameters. No conductive
gel was used. A flexible spring is placed in the substrate of each pin
of MEA to assure a full contact between the uneven skin surface
and all of the electrodes. The delivery parameters such as pulse
numbers, electric field and current were monitored.
Living Imaging of Luciferase Expression
At different selected time points after delivery, animals were
anesthetized then administrated intradermally with 50 mL or
200 mLof D-luciferin with 7.5 mg/mL in PBS buffer (Goldbio, St.
Louis, MO, USA). Assessment of photonic emissions using the
IVIS Spectrum system (Caliper Life Sciences, Hopkinton, MA,
USA)) was performed 1.5 minutes after injection of D-luciferin.
Background luminescence was determined by measuring lumines-
cence from area without DNA injection and electric field.
GFP Expression
Each excised sample was immediately frozen on dry ice. After
visualization of GFP expression was observed and obtained by
fluorescent stereoscope (Leica Model MZFL III, Leica, Heer-
brugg, Switzerland), the specimens were embedded in tissue freeze
media OCT compound (Electron Microscopy Sciences, Hatfield,
PA) and frozen at 280uC. Several frozen sections (8 mm thickness)
were cut from each sample. Each section was fixed in 25% acetone
in ethanol for 20 minutes and then washed twice in PBS. Sections
were dried in the dark and the coverslip mounted with
VECTASHIELDH mounting medium with DAPI (Vector Labo-
ratories, Burlingame, CA). Sections were examined by Olympus
BX51 fluorescent microscopy (Olympus, Tokyo, Japan) for the
presence of GFP.
Histological Analysis
Each specimen was embedded, sectioned and fixed as
mentioned above. Sections were dehydrated in 95% ethanol 30
seconds, stained in hematoxylin solution 5 minutes, rinsed with tap
water 3 minutes, classified in 1% acid alcohol for 10 seconds,
washed with running tap water for 1 minute, blued in 0.2%
ammonia solution for 30 seconds, washed in running tap water for
3 minutes, rinsed in 95% alcohol, 10 dips, counterstained in eosin
Y solution for 45 seconds, dehydrated through 95% alcohol, 2
changes of absolute alcohol, 10 dips each, cleared in 2 changes of
xylene, 10 dips each, mounted with xylene based mounting
medium. Sections were examined by Olympus BX51 microscopy.
ELISA assay for human factor IX
Skin samples were harvested and immediately frozen on dry ice
at different time points after EP delivery. The supernatants were
collected after skin homogenization in PBS with protein inhibitor
(Cat. 04693132001, Roche Applied Science, Mannheim, Ger-
many). At different time points, 400 mL blood were collected in
serum collecting tubes with 50 mL 0.5 M EDTA and plasma
collected after centrifugation. To perform an ELISA assay, a Nunc
96-well ELISA plate was coated with mouse anti-hFactor IX
antibody (Sigma Aldrich, St. Louis, MO, USA) at 200 ng/well in
PBS and incubated at 4uC overnight. Human factor IX (Promega,
Fitchburg, WI, USA) was serially diluted as a standard. HRP-goat
anti-hFactor IX (1:2000, Enzyme Research Labs, South Bend, IN,
USA) was the detection antibody. Substrate reagent (R&D System,
Minneapolis, MN, USA) was added and finally 1N sulfuric acid
stop solution was added. The plate was read by Multiskan MCC
Microplate Reader (Fisher Scientific) and the concentration of
factor IX was determined using a standard curve.
Statistical Analysis
All values are reported as the mean 6 SD. Area under curves
(AUCs) for luciferase or human factor IX expression are calculated
for analysis of gene expression over the time among different
delivery groups. The linear trapezoidal method is used for the
rising phase of gene expression while logarithmic trapezoidal
method is used for the decreasing phase of expression. Analysis
was completed by One Way ANOVA for many groups or 2-tailed
Student’s t-test for 2 groups. Repeated Measures ANOVA was
used to evaluate the differences of animal weight increase after
treatment. Statistical significance was assumed at p,0.05. All
statistical analysis was completed using the SigmaPlot 11.0 (Aspire
Software International, Ashburn, VA).
Results
Significant elevation of gene expression and
prolongation of expression after intradermal DNA
administration followed by topical non-invasive skin GET
Because electrogene delivery had not been previously per-
formed in hairless guinea pig skin, we first optimized the delivery
condition by adopting the parameters from our previous work in
Hartley guinea pigs [12], while testing a wider range of electric
fields. As shown in Fig 1A, the expression level of luciferase
positively correlated to the applied voltage up to 50 V. Although
all delivery groups with above 50 V showed significantly increased
gene expression compared to DNA injection only (p,0.05 for all 3
groups vs DNA injection only), the level of gene expression was no
longer enhanced when the applied voltage was further increased
up to 70 V. In contrast to intradermal DNA injection only, GET
remarkably enhanced gene expression 2 to 4 logs and prolonged
gene expression up to 12 to 15 days. While the expression level of
non-GET-treated groups was relatively low at day one and rapidly
dropped at day two, the gene expression of GET-treated groups
maintained high levels until peak expression was reached at day
eight then slowly decreased to background level after day 19 or
later.
We next addressed the feasibility of increasing the gene
expression by the extension of the treated areas. We compared a
50 mL DNA injection with a single GET application to a four-fold
increase in plasmid and delivery area, This resulted in a 3.94 to
6.02 fold increase in luciferase from days one to eight after delivery
Gene Delivery to Epidermis by Electrotransfer
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(Fig 1B, p,0.05 for 4 GET vs 1 GET). Eight days after
electrogene delivery, gene expression in both groups gradually
decreased. However, at day 21 post-delivery, the gene expression
in the group treated in the larger area maintained 1 log higher
than the control group without GET. For the group receiving the
single GET application, gene expression was similar to the
respective control group.
Exclusively epidermal gene expression after topical DNA
delivery with a noninvasive MEA
Using fluorescence stereoscopy, a weak and small area of green
florescence protein (GFP) expression was present at the center of
injection site in non-electrotransferred skin one day after
intradermal DNA injection alone. In contrast, GET enhanced
the gene expression with increase of not only the intensity of gene
expression but also expression area (Fig 2A), which was slightly
larger than the surface covered by MEA. To assess the distribution
of transgene expressing cells after non-invasive surface GET, cross-
sections of the skin were labeled with DAPI and observed by
fluorescent microscopy. All GFP expressing cells from GET-
treated skin were located in the epidermis at post-GET delivery
day 2 or day 7 (Fig. 2B). For skin receiving DNA injection alone,
no expression was observed in the epidermis at either day 2 or day
7 (Fig. 2B). The distribution pattern of transgene expressing cells is
the same as we observed in Hartley guinea pigs [12] although their
skin histologies are not identical. As previously mentioned, skin
receiving DNA injection only expressed a low level of luciferase
and GFP one day after gene delivery (Fig. 1 and Fig. 2A). In fact, a
few GFP expressing cells in skin without pulse delivery were
observed in the dermis surrounding the DNA injection site but not
in the epidermis (Fig. 2C). It appears that epidermal gene
expression only resulted from GET.
Minimal and mild skin changes after GET with a
noninvasive MEA
Another important issue is the adverse effect of GET with the
non-invasive MEA. Based on gross observation, GET with
parameters selected in this study did not cause any severe tissue
damage such as skin burning, necrosis or scar formation (Fig. 3A).
Muscle twitch also was greatly reduced with this non-invasive
MEA compared to plate electrode or needle array. Skin redness
remained one day after GET delivery, but faded by day 2. Only
the needle track at the injection site was seen at post-delivery day 5
(Fig. 3A). Tissue damage was also evaluated by hematoxylin and
eosin staining. Microscopically, no significant morphological
changes at day 2 or day 7 were observed in skin with GET
treatment (Fig 3B). The focal cell vacuolization or degeneration of
the skin, which was seen in the epidermal layer in our previous
study with Hartley guinea pigs (Heller et al. 2007), was not
observed in this study. Overall, these skin changes with gross
observation and histology were milder than Hartley guinea pig
skin treated with same GET parameters.
The average body weight increase of plasmid and GET treated
HLGPs was 10.7% to 22.7% greater than those without GET
treatment in our observational period from day 2 to day 19 (Fig 4,
p,0.001 for GET or 4 GET vs DNA alone control). The change
of body weight appears related to GET only but not the size of
GET treatment. Increasing delivery to four areas did not further
enhance the level of body weight increase (Fig. 4), although it was
observed to further significantly increase transgene expression
(Fig. 1a).
Human factor IX production in the HLGP skin and
secretion into systemic circulation after GET to the skin
with the non-invasive MEA
Topical expression of a therapeutic protein, human factor IX,
was next assessed by our established approach. A significant level
of human Factor IX protein in HLGP skin was achieved with
electrotransfer (Fig 5A, p = 0.036). Three weeks after delivery, no
significant factor IX product was detected. In contrast, plasmid
DNA injection alone showed expression of factor IX only at day 2
of 1.5 ng/delivery area. Several groups have demonstrated the
expression of human factor IX or growth hormone in mouse
epidermis could reach the systemic circulation [21–23]. Here we
Figure 1. Kinetic of gene expression in HLGP skin after intradermal DNA injection and non-invasive GET. A, Time course of luciferase
expression in HLGP skin after delivery by different electric fields at day 0. 50 mL DNA and 1 pulse delivery for all delivery groups, IO: no pulse delivery;
GET: applied voltage of 30, 40, 50, 60 or 70. *: p,0.05 for GET-50, GET-60 or GET-70 vs IO. B, Time course of luciferase expression in HLGP skin after
delivery to different sizes of skin. Delivery groups, 50-IO: 50 mL DNA without pulse delivery; 50-GET: 50 mL DNA with 1 pulse delivery on the injection
site; 50 mLx4-IO: 4 injections with 50 mL DNA without pulse delivery; 50 mLx4-GET: 4 injections with 50 mL DNA and each pulse delivery on the
injection site. Bars represent mean 6 SD. 4–6 sites were analyzed for each delivery parameter, p/s = photons/second. * p,0.05 for 4650-GET vs 50-
GET and 4650-GET vs 4650-IO.
doi:10.1371/journal.pone.0073423.g001
Gene Delivery to Epidermis by Electrotransfer
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e73423
observed if our direct topical electrotransfer approach could do the
same. Plasma was collected at different time points before and
after topical gene delivery and analyzed by ELISA. No increase of
factor IX protein in HLGP plasma was observed after DNA
injection only. Although a low level increase of factor IX protein,
0.2 ng/ml to 1.7 ng/ml, was observed from days 2 to 15 after
electrotransfer (Fig 5B), there is no statistically significant
difference among control and delivery groups.
Discussion
The xenograft human skin-SCID chimera has been reported as
a valuable model for pathological research of several skin disorders
including psoriasis, cutaneous lupus, pemphigus, vitiligo and
androgenetic alopecia [24–26]. However, the immune deficiency
of the xenograft model limits its application for immunomodula-
tion, including vaccination and immune therapy for skin cancer. A
Figure 2. Distribution of GFP-expressing cells in HLGP skin after i.d. DNA injection and non-invasive GET. Skin samples were collected
post-delivery day 1, day 2 or day 7. Samples were analyzed by fluorescent stereoscopy or microscopy. IO: DNA injection only without pulse delivery;
GET: DNA injection with pulse delivery. A, One representative picture of 3 treated sites. (B, C) Total 6 cryosections (2 sections per sample) of each
delivery were analyzed. Cell nuclei were blue-stained by DAPI. GFP-expressing cells were shown green and indicated by arrow. B, One representative
section of each delivery was presented for post-delivery day 2 or day 7(magnification = 100, scale bar = 200 mm). C, One representative section from
post-delivery day 1 (magnification = 200, scale bar = 100 mm).
doi:10.1371/journal.pone.0073423.g002
Figure 3. Gross observation and histology of HLGP skin after i.d. DNA injection and non-invasive GET. A, Skin observation after
delivery. Pictures were taken at post-delivery day 1, day 5 and day 8. One representative picture of 4 to 6 sites was shown here. Delivery group, IO:
50 mL DNA without pulse delivery; GET: 50 mL DNA with pulse delivery. B, H&E stained skin samples. One representative of 3 treated sites was
presented here for post-delivery day 2 or day 7 (magnification = 200, scale bar = 100 mm).
doi:10.1371/journal.pone.0073423.g003
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few skin electrotransfer studies have been performed in rabbit or
pig skin, while most studies of skin GET have been performed in
mouse or rat skin [8], which is significantly different from human
skin. The structure of HLGP skin, including thickness, histology
and number of microvessels, is very similar to human skin [20]. In
addition, these animals are euthymic and immunocompetent,
which makes HLGP skin a good alternative for human skin
research. A major disadvantage of the HLGP model is the
unavailability of antibodies for identification of specific cell types.
Our contact electrode (MEA) is one of the most suitable systems
for delivery to the skin epidermis. Skin GET can result in
transfected cells in the epidermis, dermis, hypodermis, and even
the muscle layer, dependent on the electrodes, injection tech-
niques, animal species and plasmid designs used, for example
whether tissue specific promoters are involved. GET with plate
electrodes transfects cells to the mouse dermis [27], the epidermis
of xenograft human skin [9], or both epidermis and dermis of rat
[13]. GET with needle electrodes or needle arrays can reach the
deep layers of the skin and result in transgenic cells in the dermis,
epidermis, hypodermis and subcutaneous muscle layer of the
mouse or rat [14,28] or dermis of the pig [29]. Interestingly, both
epidermis and muscle layer were transfected by pulse delivery with
plate-and-fork electrode as was shown with a variation of the time-
course of expression [11]. Moreover, transfection in the lower
dermis of rabbit was achieved by GET with tweezer electrodes
[30]. In this study and in our previous work [12], we demonstrated
that targeted transgenic expression to the epidermis can be
obtained in Hartley guinea pig or HLGP skin after GET with the
MEA. A similar result was observed in another study performed in
Hartley guinea pig skin using a similar, but more invasive
electrode [15]. The computer simulation of the skin model for
delivery with the meander electrode showed that majority (.90%)
of electric field acted in the epidermal layer of skin within a depth
of 125 mm [31]. It is understandable that GET with surface
Figure 4. Body weight increase of HLGP after i.d. DNA injection
and non-invasive GET. Delivery group, IO: 50 mL DNA without pulse
delivery; GET: 50 mL DNA with 1 pulse delivery on the injection site;
4GET: 4 injections with 50 mL DNA and each pulse delivery on the
injection site. Bars represent mean 6 SD. 4 animals were analyzed for
each delivery group. * p,0.05 for 4GET or GET vs IO by One Way RM-
ANOVA.
doi:10.1371/journal.pone.0073423.g004
Figure 5. Human factor IX protein in HLGP after i.d. DNA (pNGVL3/CMVi/hFIXm1) injection and non-invasive GET. A, Human factor IX
in HLGP skin. Delivery groups, IO: 50 mL DNA without pulse delivery; GET: 50 mL DNA with 1 pulse delivery on the injection site. Bars represent mean
6 SD. 3 sites were analyzed for each delivery. * p,0.05 by Student’s t-test. B, Human factor IX in HLGP plasma. Delivery groups, IO: 50 mL DNA
without pulse delivery; GET: 50 mL DNA with 1 pulse delivery on the injection site. 4GET: 4650 mL DNA with 4 pulse delivery on the injection site. Bars
represent mean 6 SD. 4 HLGPs were analyzed for each delivery group.
doi:10.1371/journal.pone.0073423.g005
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contact electrodes like the MEA results in exclusively transgene
expression in the epidermis.
Several studies have reported the expression level and duration
of gene delivery with skin GET [8–14], it is hard to make an
accurate comparison among them because different animal species
were used and delivery of various transgenes was performed using
a variety of pulse parameters and electrodes. Obviously, gene
transfection into different cell types can lead to various levels and
kinetics of transgenic expression because the cell half-lives are
varied. In addition, the variation in half-lives of gene products can
contribute to the duration of expression. It is well known that
transfection of stable cells such as muscle fibers can result in
relatively high and long-term gene expression, while transfection
of fast growing cells such as cancer cells produces a very short
duration of gene expression. Skin GET with a plate electrode
either in mice or rats can produce transgene expression with
duration of two weeks [10,13], which is similar in time course to
our studies with guinea pig or HLGP skin with MEA GET.
However, the patterns of transgene expression are different
between GET with a plate electrode and GET with the MEA.
The former results in a spike of expression at days 1 to 2 in the rat
or day 9 in the mouse while the latter maintains a high level
expression for 8 to 12 days. The difference of expression patterns
can be explained by the distribution of the transfected cells. GET
with plate electrode will transfect both epidermal and dermal cells,
while GET with the MEA will only transfect into epidermal cells.
If the total amount of expression or the area under curve is
determined, delivery with the MEA achieves a higher total
expression.
Compared to other skin GET, such as plate or needle
electrodes, the adverse effects caused by MEA were largely
reduced. Muscle contraction caused by GET was decreased, and
no serious skin damage was observed grossly and histologically.
We observed that the side effects were similar or milder in HLGP
than Hartley guinea pigs or rat treated by MEA with same
parameters[12,16]. Noticeably, significant weight gain was related
to skin GET with MEA for HLGP. We haven’t observed this
phenomenon on Hartley guinea pigs or rat under same condition.
Because of small sample size, only 4 animals per group, we don’t
know if it’s real. To confirm this result, we will recommend it’s
necessary to repeat the same experiment with large group of
animals.
Previously, we demonstrated that gene expression after GET
with the MEA was significantly higher than GET with a plate
electrode in the Hartley guinea pig model [16]. Using the same
electrical parameters, the expression levels achieved by GET with
the MEA were different depending upon the animal species.
Among rat, Hartley guinea pig and HLGP electrotransfer with the
MEA would achieve the highest gene expression in HLGP skin,
then in the Hartley guinea pig skin [12], the relative lowest gene
expression in rat [16]. The thicker epidermis of HLGP skin is most
likely related to its higher expression level. Because of the similarity
of histology and thickness between HLGP skin and human skin we
would predict that human skin with the MEA can achieve the
same level of gene expression under the similar electrical
parameters.
Another important question is whether the protein produced in
the epidermis following GET can reach the blood circulation of
the animals and achieve a therapeutic level. In this study we
demonstrated a low level of human Factor IX (0.2 ng/ml to
1.7 ng/ml) could be detected in the HLGP circulation if a large
area of skin is GET-treated. Human factor IX could also be
detected in the circulation of nude mouse after transplanted with
keratinocytes expressing protein [22]. The big issue is very little
factor IX that actually reaches the systemic circulation. The level
of factor IX was only 0.5 ng/ml to 3 ng/ml from day 1 to day 7
after transplantation. The authors estimated that the efficiency of
factor IX secreting into circulation is only 2.6% [22]. The similar
conclusion came from a study in keratin-promoter transgenic mice
[21]. It is estimated that a graft of 25–30% total surface area is
needed to achieve 2% of normal physiological level (100 ng/ml) of
factor IX [21]. Although epidermal transgene expression may not
be practicable for hemophilic diseases which need medium to large
amount of gene production ( mg/ml to mg/ml) for replacement, it
may be feasible for systemic disorders such as a deficiency of
growth hormone (GH), adrenocorticotropic hormone or parathy-
roid hormone, in which the physiological range is pg/ml to ng/ml.
In nude mice grafted with keratin-promotor-driven GH transgenic
mouse skin, 0.1–0.4 ng/ml of human GH could be detected in the
bloodstream [23]. Considering the physiological level of human
GH is 0 to 5 ng/ml, it is possible to achieve this level by an
increase of the graft size or the area of GET-treated skin.
One advantage of skin GET with MEA is that the level of gene
expression is controllable by adjusting the treated area. We
demonstrated that the gene production could be significantly
increased proportionally by extension of GET area. To achieve
this goal, we can either treat more areas with same MEA or
expand our current MEA to larger size without change of the pin
gap so that the same parameters can be applied to this modified
MEA. In addition, our group is investigating other factors may
enhance the efficiency of GET or facilitate gene product to diffuse
into circulation meanwhile without cause of cell toxicity. So the
disadvantage of low level of gene product in the blood may be
overcome.
In conclusion, this is the first study utilizing a HLGP model with
skin features similar to human skin to characterize the GET with a
non-invasive MEA electrode. Efficient gene delivery with an
increase up to 4 logs can be achieved by GET with the MEA.
After skin GET with the MEA, exclusively epidermal expression
was observed, and high level gene expression can be maintained
for up to 12–15 days. We observed that skin changes in HLGP
caused by GET with the MEA are minimal and milder than those
in normal hair guinea pig. However, only a small portion of gene
product reached the systemic circulation of the animal. These
results suggest skin gene delivery with our approach can be a safe,
efficient, non-invasive method for skin disorders, vaccinations and
possibly systemic diseases with physiological levels that are in the
range of pg/ml to ng/ml, but may not be suitable for conditions
requiring a larger amount of gene product.
Acknowledgments
Plasmid DNA pNGVL3/CMVi/hFIXm1 was given by Dr. Kurachi (Age
Dimension Research Center, National Institute of Advanced Industrial
Science and Technology, Tsukuba, Ibaraki, Japan). We thank Dr. Loree
Heller (Frank Reidy Research Center for Bioelectrics, Old Dominion
University) for critical reading and review of the manuscript.
Author Contributions
Conceived and designed the experiments: SG RH. Performed the
experiments: SG AI GB AD RH. Analyzed the data: SG RH. Contributed
reagents/materials/analysis tools: RH. Wrote the paper: SG RH.
Gene Delivery to Epidermis by Electrotransfer
PLOS ONE | www.plosone.org 6 August 2013 | Volume 8 | Issue 8 | e73423
References
1. Khavari PA (1997) Therapeutic gene delivery to the skin. Mol Med Today 3:
533–538.
2. Trainer AH, Alexander MY (1997) Gene delivery to the epidermis. Hum Mol
Genet 6: 1761–1767.
3. Spirito F, Meneguzzi G, Danos O, Mezzina M (2001) Cutaneous gene transfer
and therapy: the present and the future. J Gene Med 3: 21–31.
4. Khavari PA, Rollman O, Vahlquist A (2002) Cutaneous gene transfer for skin
and systemic diseases. J Intern Med 252: 1–10.
5. Jensen TG (2004) Strategies for long-term gene expression in the skin to treat
metabolic disorders. Expert Opin Biol Ther 4: 677–682.
6. Gutowska-Owsiak D, Ogg GS (2012) The epidermis as an adjuvant. J Invest
Dermatol 132: 940–948.
7. Fan H, Lin Q, Morrissey GR, Khavari PA (1999) Immunization via hair follicles
by topical application of naked DNA to normal skin. Nat Biotechnol 17: 870–
872.
8. Gothelf A, Gehl J (2010) Gene electrotransfer to skin; review of existing literature
and clinical perspectives. Curr Gene Ther 10: 287–299.
9. Zhang L, Nolan E, Kreitschitz S, Rabussay DP (2002) Enhanced delivery of
naked DNA to the skin by non-invasive in vivo electroporation. Biochim Biophys
Acta 1572: 1–9.
10. Heller LC, Jaroszeski MJ, Coppola D, McCray AN, Hickey J, et al. (2007)
Optimization of cutaneous electrically mediated plasmid DNA delivery using
novel electrode. Gene Ther 14: 275–280.
11. Maruyama H, Ataka K, Higuchi N, Sakamoto F, Gejyo F, et al. (2001) Skin-
targeted gene transfer using in vivo electroporation. Gene Ther 8: 1808–1812.
12. Guo S, Donate A, Basu G, Lundberg C, Heller L, et al. (2011) Electro-gene
transfer to skin using a noninvasive multielectrode array. J Control Release 151:
256–262.
13. Pavselj N, Preat V (2005) DNA electrotransfer into the skin using a combination
of one high- and one low-voltage pulse. J Control Release 106: 407–415.
14. Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, et al. (2009) Skin
electroporation: effects on transgene expression, DNA persistence and local
tissue environment. PLoS One 4: e7226.
15. Broderick KE, Shen X, Soderholm J, Lin F, McCoy J, et al. (2011) Prototype
development and preclinical immunogenicity analysis of a novel minimally
invasive electroporation device. Gene Ther 18: 258–265.
16. Heller R, Cruz Y, Heller LC, Gilbert RA, Jaroszeski MJ (2010) Electrically
mediated delivery of plasmid DNA to the skin, using a multielectrode array.
Hum Gene Ther 21: 357–362.
17. Daynes RA, Emam M, Krueger GG, Roberts LK (1983) Expression of Ia
antigen on epidermal keratinocytes after the grafting of normal skin to nude
mice. J Immunol 130: 1536–1539.
18. Demarchez M, Asselineau D, Czernielewski J (1993) Migration of Langerhans
cells into human epidermis of "reconstructed" skin, normal skin, or healing skin,
after grafting onto the nude mouse. J Invest Dermatol 100: 648–652.
19. Gonzalez-Gonzalez E, Kim YC, Speaker TJ, Hickerson RP, Spitler R, et al.
(2011) Visualization of plasmid delivery to keratinocytes in mouse and human
epidermis. Sci Rep 1: 158.
20. Sueki H, Gammal C, Kudoh K, Kligman AM (2000) Hairless guinea pig skin:
anatomical basis for studies of cutaneous biology. Eur J Dermatol 10: 357–364.
21. Alexander MY, Bidichandani SI, Cousins FM, Robinson CJ, Duffie E, et al.
(1995) Circulating human factor IX produced in keratin-promoter transgenic
mice: a feasibility study for gene therapy of haemophilia B. Hum Mol Genet 4:
993–999.
22. Gerrard AJ, Hudson DL, Brownlee GG, Watt FM (1993) Towards gene therapy
for haemophilia B using primary human keratinocytes. Nat Genet 3: 180–183.
23. Wang X, Zinkel S, Polonsky K, Fuchs E (1997) Transgenic studies with a keratin
promoter-driven growth hormone transgene: prospects for gene therapy. Proc
Natl Acad Sci U S A 94: 219–226.
24. Raychaudhuri SP, Dutt S, Raychaudhuri SK, Sanyal M, Farber EM (2001)
Severe combined immunodeficiency mouse-human skin chimeras: a unique
animal model for the study of psoriasis and cutaneous inflammation.
Br J Dermatol 144: 931–939.
25. Gilhar A, Etzioni A (1994) The nude mouse model for the study of human skin
disorders. Dermatology 189: 5–8.
26. Sundberg JP, Beamer WG, Uno H, Van Neste D, King LE (1999) Androgenetic
alopecia: in vivo models. Exp Mol Pathol 67: 118–130.
27. Vandermeulen G, Daugimont L, Richiardi H, Vanderhaeghen ML, Lecouturier
N, et al. (2009) Effect of tape stripping and adjuvants on immune response after
intradermal DNA electroporation. Pharm Res 26: 1745–1751.
28. Gao Z, Wu X, Song N, Cao Y, Liu W (2007) Electroporation-mediated plasmid
gene transfer in rat incisional wound. J Dermatol Sci 47: 161–164.
29. Drabick JJ, Glasspool-Malone J, King A, Malone RW (2001) Cutaneous
transfection and immune responses to intradermal nucleic acid vaccination are
significantly enhanced by in vivo electropermeabilization. Mol Ther 3: 249–255.
30. Medi BM, Hoselton S, Marepalli RB, Singh J (2005) Skin targeted DNA vaccine
delivery using electroporation in rabbits. I: efficacy. Int J Pharm 294: 53–63.
31. Zhang L, Lerner S, Rustrum WV, Hofmann GA (1999) Electroporation-
mediated topical delivery of vitamin C for cosmetic applications. Bioelectrochem
Bioenerg 48: 453–461.
Gene Delivery to Epidermis by Electrotransfer
PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e73423
